SIRNAOMICS-B (02257) released its interim results, with a profit attributable to shareholders of $91,000, marking a year-on-year turnaround to profitability.
Sino Biopharmaceutical B (02257) announced its performance for the six months ending June 30, 2026. During this period, the group recorded other income of $140,000, an increase of 12.9% year-on-year; profit attributable to owners of the company was $91,000, reversing from a loss to a profit year-on-year; basic earnings per share were 0.09 cents.
SIRNAOMICS-B (02257) announced its results for the six months ending June 30, 2026, during which the group achieved other income of $140,000, an increase of 12.9% year-on-year; profit attributable to shareholders was $91,000, marking a turnaround to profitability; basic earnings per share were 0.09 cents.
Related Articles
CLIFFORDML (03686) announced its interim results, reporting a net loss of 3.372 million yuan, a year-on-year turnaround from profit to loss.
China Longyuan Power Group Corporation (00916): A-share private placement approved
AUX ELECTRIC (02580) released its interim results, with a net profit of 1.108 billion yuan, a year-on-year decrease of 40.8%.
CLIFFORDML (03686) announced its interim results, reporting a net loss of 3.372 million yuan, a year-on-year turnaround from profit to loss.
China Longyuan Power Group Corporation (00916): A-share private placement approved
AUX ELECTRIC (02580) released its interim results, with a net profit of 1.108 billion yuan, a year-on-year decrease of 40.8%.
RECOMMEND
